Editor’s Note: This article on BBI’s Colin Pritchard was published on the UW Medicine Alumni Association website, and was written by Communications Specialist Stephanie Perry.
Twenty-two years ago, Colin Pritchard, PhD ’05, MD ’07, Res. ’10, Fel. ’11, attended a guest lecture that set the trajectory of his career in medicine.
The speaker was Stephen Friend, MD, PhD. He was then the CEO of Rosetta Inpharmatics, a software analytics company dedicated to genomic research — the study of all of a person’s genes (the genome) as well as how those genes interact with each other and the environment. Using leading-edge DNA microarray technologies that allowed them to analyze entire grids of DNA sequences, Friend and his team were on the front lines of developing diagnostic tests to identify genetic indicators of cancer risk in patients.
Pritchard was only in his second year at the University of Washington School of Medicine, but he knew he had stumbled upon a new passion even before the lecture ended.
Please continue reading here.
